Optimer's Dificid positive in post-hoc Phase III analysis in cancer patients
This article was originally published in Scrip
Executive Summary
A post-hoc analysis of two Phase III clinical trials for Optimer Pharmaceuticals' Dificid (fidaxomicin) tablets as a treatment for Clostridium difficile-associated diarrhoea (CDAD) in cancer patients found higher clinical cure rates, better sustained response and lower recurrence of the bacterial infection than in study subjects who took oral vancomycin.